點擊圖片查看原圖
Recombinant CHO-K1 cells constitutively expressing human PD-L1 (Programmed Cell Death 1 Ligａnd 1, CD274, B7 homolog 1 (B7- H1), GenBank accession # NM_014143) and an engineered T cell receptor (TCR) activator. This cell lines was functionally validated in a cell-based assay.
Figure 1: Mechanism of action of TCR activator/ PD-L1 CHO Cell Line in combination with PD-1/NFAT reporter-Jurkat cell line. Jurkat T cells expressing NFAT reporter with constitutive expression of PD-1 (PD-1/NFAT Reporter Jurkat Cell Line, BPS Bioscience #60535) act as effector cells. When co-c*ted, TCR complexes on PD-1/NFAT Reporter Jurkat cells are activated by the TCR activator of TCR Activator/ PD-L1– CHO Recombinant Cell Line, resulting in expression of the NFAT luciferase reporter.
However, PD-1 and PD-L1 ligation prevents TCR activation and suppresses the NFAT-responsive luciferase activity. This inhibition can be specifically reversed by anti-mouse PD-1 or anti-mouse PD-L1 antibodies. PD-1/PD-L1 neutralizing antibodies block PD-1:PD-L1 interaction and promote T cell activation, resulting in reactivation of the NFAT responsive luciferase reporter.
更多詳情：http://www.bpsbioscience.com.cn/Products-37982681.html
https://www.chem17.com/st542058/product_37982681.html
原文鏈接：http://www.525682.com/shangji/show-19916.html，轉載和復制請保留此鏈接。
以上就是關于TCR Activator - CHO Recombina全部的內容，關注我們，帶您了解更多相關內容。
以上就是關于TCR Activator - CHO Recombina全部的內容，關注我們，帶您了解更多相關內容。
